Nociception contributes to the formation of myogenic contracture in the early phase of adjuvant ‐induced arthritis in a rat knee
This study aimed to clarify the role of nociception on the formation of joint contracture secondary to arthritis. Monoarthritis was induced by intra‐articular injections of complete Freund's adjuvant (CFA) into rat knees. On day 5 after CFA injection, the passive extension range of motion (ROM) of knee joints were measured, both before and after myotomy of knee flexors, to evaluate the extent of muscular contribution to CFA‐induced joint contracture. The steroidal anti‐inflammatory drug dexamethasone could prevent ROM restrictions completely, both before and after myotomy. On the other hand, the opioid analgesic drug...
Source: Journal of Orthopaedic Research - September 1, 2016 Category: Orthopaedics Authors: Akinori Kaneguchi, Junya Ozawa, Hideki Moriyama, Kaoru Yamaoka Tags: Research Article Source Type: research

Edwards P, Sakzewski L, Copeland L, et al. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy. Pediatrics. 136(5):895-904
(Source: PEDIATRICS)
Source: PEDIATRICS - September 1, 2016 Category: Pediatrics Tags: Administration/Practice Management Errata Source Type: research

Treatment with Botulinum Toxin Type A in Infants with Refractory Congenital Muscular Torticollis: A 10-Year Retrospective Study.
Clarice Sinn: I Have No Relevant Financial Relationships To Disclose (Source: PM and R)
Source: PM and R - September 1, 2016 Category: Rehabilitation Authors: Clarice N. Sinn, Robert J. Rinaldi Source Type: research

Poster 181 Botox Application for Recurrent Wrist Pain
Rucha Kharod: I Have No Relevant Financial Relationships To Disclose (Source: PM and R)
Source: PM and R - September 1, 2016 Category: Rehabilitation Authors: Rucha Kharod, Prateek Grover, Rimma Ruvinskaya Source Type: research

Poster 370 An International, Observational Study of Botulinum Toxin Type A in Spasticity – SPAsticity in PractiCE (SPACE)
J örg Wissel: Speakers bureau - Allergan, Ipsen, Merz, Medtronic (Source: PM and R)
Source: PM and R - September 1, 2016 Category: Rehabilitation Authors: J örg Wissel, Julian P. Harriss, Olivier Simon, Kati Sternberg, Nicolas Roche, Carlos Cantú-Brito, Svetlana E. Khatkova, Patrik Säterö Source Type: research

Poster 310 EMG Guided Botulinum Toxin Type A Injections for Functional Problems Associated to Congenital Facial Palsy: A Case Report
Isabel Rutzen: I Have No Relevant Financial Relationships To Disclose (Source: PM and R)
Source: PM and R - September 1, 2016 Category: Rehabilitation Authors: Isabel M. Rutzen, David Q. Atkins, Keryl Motta Source Type: research

Comparison of different consensuses of BTXA in different countries
Summary The most international dosing guidelines on the use of botulinum toxin type A (BTXA) drugs support a 1:1 dose relationship between OnaBTXA and IncoBTXA and 1:2.5 between OnaBTXA and AboBTXA. However, different facial zones demonstrate different doses conversion ratios. The comparative analysis of nine consensuses on the use of Abo‐, Ona‐, and IncoBTXA in the United States, Russia, and Europe has been performed. We conducted a review of publications adopting the key words “botulinum toxin consensus,” “botulinum toxin guideline.” Information search has been carried out primarily in special...
Source: Journal of Cosmetic Dermatology - September 1, 2016 Category: Dermatology Authors: Alisa A Sharova Tags: Review Article Source Type: research

Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial
Conclusions: Botox and AC medications have similar costs and effectiveness in the first 6 months of UUI treatment. If costs and outcomes are considered through 9 months, Botox may have significantly lower costs but similar UUI symptom control as AC. (Source: Female Pelvic Medicine and Reconstructive Surgery)
Source: Female Pelvic Medicine and Reconstructive Surgery - August 31, 2016 Category: OBGYN Tags: Original Articles Source Type: research

Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
CONCLUSIONS: It has been demonstrated that in real clinical practice, the cost per patient and year for treatment of paediatric spasticity was lower when abobotulinumtoxinA was used. PMID: 27570991 [PubMed - as supplied by publisher] (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 31, 2016 Category: Drugs & Pharmacology Authors: Tapias G, García-Romero M, Crespo C, Cuesta M, Forné C, Pascual-Pascual SI Tags: Farm Hosp Source Type: research

A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon
Local injections with Botulinum Toxin Type-A (Btx-A) will improve blood flow to the hands of patients with Raynaud ’s phenomenon secondary with scleroderma, as measured by Laser Doppler Imaging and patient-reported outcomes. (Source: The Journal of Hand Surgery)
Source: The Journal of Hand Surgery - August 25, 2016 Category: Surgery Authors: Ricardo J. Bello, Carisa M. Cooney, Eitan Melamed, Keith E. Follmar, Fred J. Wigley, Scott D. Lifchez Tags: Abstract Source Type: research

POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia
ConclusionThe cost-effectiveness of POEM and LM is equivalent. Myotomy, either surgical or endoscopic, is more cost-effective than BI due to high failure rates of the economical intervention. When treatment is being considered BI should be utilized in patients with less than 2-year life expectancy. Pneumatic dilations are cost-effective and are an acceptable approach to treatment of achalasia, although myotomy has a lower relapse rate and is cost-effective compared to PD after 2  years. (Source: Surgical Endoscopy)
Source: Surgical Endoscopy - August 17, 2016 Category: Surgery Source Type: research

IncobotulinumtoxinA: A Review in Upper Limb Spasticity
AbstractIntramuscular incobotulinumtoxinA (Xeomin®) is indicated for the treatment or improvement of adult patients with upper limb spasticity (featured indication), cervical dystonia, blepharospasm and glabellar lines. It is a highly purified formulation of botulinum toxin type A that inhibits acetylcholine signalling at neuromuscular junctions, reducing muscle hypertonia. This narrative review discusses the clinical use of incobotulinumtoxinA in adults with upper limb spasticity and summarizes its pharmacological properties. In single-treatment phase 3 trials, compared with placebo, incobotulinumtoxinA treatment impr...
Source: Drugs - August 16, 2016 Category: Drugs & Pharmacology Source Type: research

Botulinum Toxin Type A Inhibits α-Smooth Muscle Actin and Myosin II Expression in Fibroblasts Derived From Scar Contracture
This study aimed to explore the effect of BTXA on α-SMA and myosin II expression in fibroblasts derived from SC and to elucidate its actual mechanism further. Methods: Fibroblasts were isolated from tissue specimens of SC. Fibroblasts were cultured in Dulbecco modified Eagle medium with different concentrations of BTXA and their proliferation was analyzed through the tetrazolium-based colorimetric method at 1, 4, and 7 days. Proteins of α-SMA and myosin II were checked using Western blot in fibroblasts treated with different concentrations of BTXA at 1, 4, and 7 days. Results: Fibroblasts without BTXA treatme...
Source: Annals of Plastic Surgery - August 13, 2016 Category: Cosmetic Surgery Tags: Research Source Type: research

Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study
Botulinum toxin (BTX) has been widely used to treat adductor spasmodic dysphonia (ADSD). Most commercially available forms of BTX require reconstitution before use, which may increase the risk of contamination and requires careful titration. Recently, a liquid-type BTX type A (BTX-A) has been developed, which should simplify the procedure and enhance its efficacy. Herein, we present a prospective pilot study to investigate the efficacy and safety of liquid-type BTX-A in the treatment of ADSD. (Source: Journal of Voice)
Source: Journal of Voice - August 9, 2016 Category: ENT & OMF Authors: Wonjae Cha, Jeon Yeob Jang, Soo-Geun Wang, Ji-Heon Kang, Min-Gyu Jo Source Type: research

Is Botulinum Toxin Type A a Valuable Adjunct During Femoral Lengthening? A Randomized Trial.
CONCLUSIONS: Local injection of 200 IU BtX-A in the quadriceps muscles does not appear to reduce distraction-induced pain nor enhance ROM in the hip or knee during femoral lengthening. Additional studies are needed to evaluate the effect of larger doses or different injection methods. Based on our findings, we do not recommend routine use of botulinum injections during limb lengthening and believe any further use of this drug should only be in the context of a controlled trial. LEVEL OF EVIDENCE: Level II, therapeutic study. PMID: 27506971 [PubMed - as supplied by publisher] (Source: Clinical Orthopaedics and Related Research)
Source: Clinical Orthopaedics and Related Research - August 9, 2016 Category: Orthopaedics Authors: Park H, Shin S, Shin HS, Kim HW, Kim DW, Lee DH Tags: Clin Orthop Relat Res Source Type: research

Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm
AbstractBackground/aimsTo evaluate the effects of botulinum toxin type A (BTX-A) treatment in patients with benign essential blepharospasm (BEB) by monitoring the ocular surface and ocular higher-order aberrations (HOAs) before and after treatment.MethodsThe present study reports a prospective case series of 38 patients (76 eyes, 11 men and 27 women; mean age 66.8  ± 9.8 years) with BEB who underwent BTX-A treatment at Kokura Memorial Hospital between 2013 and 2014. Patients were evaluated for ophthalmoscopic findings, Schirmer I test, tear film break-up time (t-BUT), HOAs, fluctuation index (FI), sta...
Source: Japanese Journal of Ophthalmology - August 8, 2016 Category: Opthalmology Source Type: research

Adverse Events of Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review and Meta-Analysis
AbstractBackgroundBotulinum toxin A (BTX-A) is a medical product that is used widely in cosmetics, and concern over the safety profile has increased among injectors and patients.ObjectiveThe purpose was to enhance the statistical effect size using a meta-analysis to detect the incidence rate of adverse events (AEs) in the treatment of facial wrinkles.MethodsA systematic search was performed for randomized, double-blind, placebo-controlled trials published through July 2015.ResultsWe searched 16 trials, including 42,405 individual participants, and found that in all enrolled facial rejuvenation studies, patients in the BTX-...
Source: Aesthetic Plastic Surgery - August 5, 2016 Category: Cosmetic Surgery Source Type: research

Frontal Alopecia after Repeated Botulinum Toxin Type A Injections for Forehead Wrinkles: An Underestimated Entity?
Conclusion: Dermatologists should be aware of the possible occurrence of frontal alopecia after repeated injections of botulinum toxin type A for forehead wrinkles.Skin Appendage Disord 2016;2:67-69 (Source: Skin Appendage Disorders)
Source: Skin Appendage Disorders - August 4, 2016 Category: Dermatology Source Type: research

Orofacial Movement Disorders
Publication date: August 2016 Source:Oral and Maxillofacial Surgery Clinics of North America, Volume 28, Issue 3 Author(s): Glenn T. Clark, Saravanan RamTeaser Orofacial movement disorders (OMDs) include dystonia, dyskinesia, drug-induced extrapyramidal reactions, and bruxism. The definition, epidemiology, pathophysiology, clinical features, and management are detailed. OMDs are often disabling and affect patients’ overall quality of life with pain, difficulty chewing food, speech difficulty, drooling, and social embarrassment. Management involves medications, botulinum toxin injections, and peripheral or central su...
Source: Oral and Maxillofacial Surgery Clinics of North America - August 2, 2016 Category: ENT & OMF Source Type: research

Orofacial Movement Disorders.
Abstract Orofacial movement disorders (OMDs) include dystonia, dyskinesia, drug-induced extrapyramidal reactions, and bruxism. The definition, epidemiology, pathophysiology, clinical features, and management are detailed. OMDs are often disabling and affect patients' overall quality of life with pain, difficulty chewing food, speech difficulty, drooling, and social embarrassment. Management involves medications, botulinum toxin injections, and peripheral or central surgery. Botulinum toxin injections are the most effective management, often used in conjunction with medications. Surgery is the last resort for patie...
Source: The Surgical Clinics of North America - August 1, 2016 Category: Surgery Authors: Clark GT, Ram S Tags: Oral Maxillofac Surg Clin North Am Source Type: research

Botulinum Toxin A: Evolving Treatment Strategies for the Chronic Pelvic Pain Patient
Abstract Chronic pelvic pain syndrome (CPPS) is defined as pain perceived within the structures of the male or female pelvis of at least 6-month duration. The management of CPPS in both men and women poses a challenge to both the clinician and the patient. Botulinum toxin type A (BoNT-A) is known to block the release of neurotransmitters at the neuromuscular junction but also appears to have anti-nociceptive and anti-inflammatory effects. BoNT-A has been used for over two decades to treat conditions associated with pathological muscle hyperactivity. There is emerging evidence that BoNT-A may play a role in treating CPPS w...
Source: Current Bladder Dysfunction Reports - July 29, 2016 Category: Urology & Nephrology Source Type: research

Orofacial Movement Disorders
Orofacial movement disorders (OMDs) include dystonia, dyskinesia, drug-induced extrapyramidal reactions, and bruxism. The definition, epidemiology, pathophysiology, clinical features, and management are detailed. OMDs are often disabling and affect patients ’ overall quality of life with pain, difficulty chewing food, speech difficulty, drooling, and social embarrassment. Management involves medications, botulinum toxin injections, and peripheral or central surgery. Botulinum toxin injections are the most effective management, often used in conjuncti on with medications. Surgery is the last resort for patients who fa...
Source: Oral and Maxillofacial Surgery Clinics - July 28, 2016 Category: ENT & OMF Authors: Glenn T. Clark, Saravanan Ram Source Type: research

Botulinum Toxin for Rhinitis
Abstract Purpose of Review Rhinitis is a common clinical entity. Besides nasal obstruction, itching, and sneezing, one of the most important symptoms of rhinitis is nasal hypersecretion produced by nasal glands and exudate from the nasal vascular bed. Allergic rhinitis is an IgE-mediated inflammatory reaction of nasal mucosa after exposure to environmental allergens. Idiopathic rhinitis describes rhinitis symptoms that occur after non-allergic, noninfectious irritants. Specific allergen avoidance, topical nasal decongestants, nasal corticosteroids, immunotherapy, and sinonasal surgery are the main treatment options. Beca...
Source: Current Allergy and Asthma Reports - July 26, 2016 Category: Allergy & Immunology Source Type: research

Impact of botulinum toxin A injection on esophageal anastomosis in a rabbit model
Conclusion Local administration of BTX-A for esophagoesophagostomy significantly reduced postoperative anastomotic stricture with less fibrosis than that observed in the control group. Reduced anastomotic tension with BTX-A presumably contributed to better anastomotic healing. Determining the optimum dose of BTX-A is necessary for clinical application. (Source: Pediatric Surgery International)
Source: Pediatric Surgery International - July 26, 2016 Category: Surgery Source Type: research

Botox ®: A 22 year experience
(Source: Operative Techniques in Oculoplastic, Orbital and Reconstructive Surgery)
Source: Operative Techniques in Oculoplastic, Orbital and Reconstructive Surgery - July 22, 2016 Category: Surgery Authors: Bosniak, Stephen Cantisano-Zilkha, Marian Source Type: research

Botulinum toxin type A  for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox®) or abobotulinumtoxinA (Dysport®) make a difference?
Publication date: 2014 Source:Yearbook of Urology, Volume 2014 Author(s): E.S. Rovner (Source: Yearbook of Urology)
Source: Yearbook of Urology - July 22, 2016 Category: Urology & Nephrology Source Type: research

Evaluation of using botulinum toxin (A) in the treatment of  myofacial pain syndrome
Publication date: September 2015 Source:Tanta Dental Journal, Volume 12, Issue 3 Author(s): O.M. Zayed, M.M.S. Khedr, A.A.M. Sadakah, A.E. El-deeb Myofacial pain syndrome (MPS) is a disorder which has become a topic over the past two decades and nowadays .10 patients (9 female & 1 male) complaining of unilateral MPS were injected with botulinum toxin type A(BTX-A) in masseter and temporalis muscles extra orally under electromyographic guidance (EMG) since they are the primary muscles responsible for pain in ear region and temporal headache respectively, which cause limitation of mandibular movement and d...
Source: Tanta Dental Journal - July 21, 2016 Category: Dentistry Source Type: research

Inhibitory Effects of Botulinum Toxin Type A on Pyloric Cholinergic Muscle Contractility of Rat.
Authors: Zhao P, Sun HX, Chu M, Hou YP Abstract Botulinum toxin type A (BTX-A) selectively cleaves synaptosomal-associated protein of 25 kDa (SNAP-25) and results in inhibition of the fusion of synaptic vesicles containing neurotransmitters with the presynaptic membrane to undergo exocytosis and release. The aim of this study was to investigate whether BTX-A inhibited the pyloric smooth muscle contractility induced by acetylcholine (ACh) after BTX-A-mediated cleavage of SNAP-25 antagonized by toosendanin (TSN). Three groups of rat pyloric muscle strips were studied in vitro. All strips were allowed to equilibrate f...
Source: The Chinese Journal of Physiology - July 20, 2016 Category: Physiology Tags: Chin J Physiol Source Type: research

Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.
CONCLUSION: MOBILITY is the largest prospective study to date to provide QoL data over a variety of therapeutic indications following treatment with onabotulinumtoxinA. Although the QoL burden varies by disease, data suggest that long-term treatment may help improve or maintain QoL over time. PMID: 27430524 [PubMed - as supplied by publisher] (Source: The Canadian Journal of Neurological Sciences)
Source: The Canadian Journal of Neurological Sciences - July 19, 2016 Category: Neurology Authors: Jog M, Wein T, Bhogal M, Dhani S, Miller R, Ismail F, Beauchamp R, Trentin G Tags: Can J Neurol Sci Source Type: research

Botulinum toxin for chronic pain conditions
Botulinum neurotoxin (BoNT), derived from Clostridium botulinum, a Gram-positive anaerobic bacterium, was first used for therapeutic purposes in 1980 for treatment of strabismus. Since that time, its use has expanded for a multitude of cosmetic and therapeutic indications. There are seven BoNT serotypes of which there are currently four BoNT versions available in the United States, onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxin A (Xeomin), and rimabotulinumtoxinB (Myobloc). (Source: Disease a Month)
Source: Disease a Month - July 14, 2016 Category: Infectious Diseases Authors: Rachel Kermen Source Type: research

Topical glycopyrrolate reduces axillary hyperhidrosis
This study determines the initial effectiveness of 1% and 2% topical glycopyrrolate spray and compares this with Botulinum toxin type A injections for the management of axillary hyperhidrosis. MethodsIn a non‐randomized, consecutive patient, prospective questionnaire, treatment comparison study, 40 patients with axillary hyperhidrosis were allocated to one of four study groups (10 patients to each group): (a) 1% glycopyrrolate spray, (b) 2% glycopyrrolate spray, (c) subcutaneous Botulinum toxin type A injections, (d) no treatment. Clinical outcomes were measured by comparing a prospectively administered questionnaire, co...
Source: Journal of the European Academy of Dermatology and Venereology - July 13, 2016 Category: Dermatology Authors: D.M. Baker Tags: Original Article Source Type: research

Esophagectomy for end‐stage achalasia
End‐stage achalasia is rarely effectively addressed with conservative treatments, as food must traverse a serpiginous route to reach the stomach. Botox injections in the setting of end‐stage achalasia will likely provide minimal temporary palliation at best, pneumatic dilation has higher risks of perforation, and laparoscopic myotomy, while minimally invasive, has presented poor results. Under these circumstances, there are many proposed procedures to restore a viable alimentary condition to patients, from partial to subtotal resection of the esophagus; each of procedures confers both advantages and specific risks. Sub...
Source: Annals of the New York Academy of Sciences - July 8, 2016 Category: Science Authors: Valter Nilton Felix Tags: Original Article Source Type: research

Esophagectomy for end ‐stage achalasia
End‐stage achalasia is rarely effectively addressed with conservative treatments, as food must traverse a serpiginous route to reach the stomach. Botox injections in the setting of end‐stage achalasia will likely provide minimal temporary palliation at best, pneumatic dilation has higher risks of perforation, and laparoscopic myotomy, while minimally invasive, has presented poor results. Under these circumstances, there are many proposed procedures to restore a viable alimentary condition to patients, from partial to subtotal resection of the esophagus; each of procedures confers both advantages and specific risks. Sub...
Source: Annals of the New York Academy of Sciences - July 8, 2016 Category: Science Authors: Valter Nilton Felix Tags: Original Article Source Type: research

Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study
This study provides class IV evidence that BoTox-A is safe , and could be beneficial in the short term and long term in a subset of ALS patients with moderate-to-severe spasticity. (Source: Journal of Neurology)
Source: Journal of Neurology - July 6, 2016 Category: Neurology Source Type: research

Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia : a systematic review and meta-analysis of randomized controlled trials
Abstract Background Several different interventions have been examined to alleviate pain and reduce frequency of trigeminal neuralgia (TN) paroxysms. However, some patients continue to have persistent or recurrent painful attacks. Using a systematic review and meta-analysis approach, we aimed to synthesize evidence from published randomized controlled trials (RCTs) regarding safety and efficacy of botulinum toxin type A (BTX-A) as a possible emerging choice of treatment for TN. Methods We conducted an electronic search in 10 databases/electronic s...
Source: The Journal of Headache and Pain - July 5, 2016 Category: Neurology Source Type: research

Achalasia: from diagnosis to management
Achalasia is an esophageal motility disorder associated with abnormalities in peristalsis and lower esophageal sphincter (LES) relaxation. The etiology of the disease remains elusive. It is often misdiagnosed initially as gastroesophageal reflux disease. Patients with achalasia often complain of dysphagia to solids and liquids but may focus on regurgitation as the primary symptom, leading to the early misdiagnosis. Chest pain, weight loss, and occasional vomiting may be additional symptoms encountered in those with achalasia. The disease may be suspected on the basis of clinical presentation, but diagnosis depends on class...
Source: Annals of the New York Academy of Sciences - July 1, 2016 Category: Science Authors: Michael F. Vaezi, Valter N. Felix, Roberto Penagini, Aurelio Mauro, Eduardo Guimar ães Hourneaux Moura, Leonardo Zorrón Cheng Tao Pu, Jan Martinek, Erwin Rieder Tags: Original Article Source Type: research

Diverse Effects of 3 Selective Serotonin Reuptake Inhibitors on Bruxism in a Depressive Patient Treated With Botox Therapy: A Case Report
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - June 30, 2016 Category: Psychiatry Tags: Letters to the Editors - Case Reports Source Type: research

Paralysis of the orbicularis muscle of the eye using botulinum toxin type A in the treatment for dry eye
ConclusionsThe injection of botulinum toxin A in the medial part of the lower eyelid is an effective and safe procedure that temporally improves some of the signs and symptoms of patients with dry eye. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - June 27, 2016 Category: Opthalmology Authors: Juan Carlos Serna‐Ojeda, Angel Nava‐Castaneda Tags: Original Article Source Type: research

Complications of botulinum toxin injections for treatment of esophageal motility disorders †
Summary In achalasia and spastic esophageal motility disorders, botulinum toxin (botox) injection is considered an effective and low‐risk procedure for short‐term symptom relief. It is mainly offered to medically high‐risk patients. However, no analysis of risks of botox injections has been performed. To determine the incidence and risk factors of procedure‐related complications after esophageal botox injections, we analyzed the records of all patients undergoing botox injection therapy for esophageal motility disorders at four university hospitals in Europe and North America between 2008 and 2014. Complications we...
Source: Diseases of the Esophagus - June 24, 2016 Category: Gastroenterology Authors: Froukje B. van Hoeij, Jan F. Tack, John E. Pandolfino, Joel M. Sternbach, Sabine Roman, Andr é J. P. M. Smout, Albert J. Bredenoord Tags: Original Article Source Type: research

Chronic post-surgical pain following the placement of dental implants in the maxilla: A case series.
CONCLUSIONS: Persistent pain after dental implant placement may occur with no apparent organic cause and without any neurosensory deficits. Practitioners must be aware of chronic post-surgical neuropathic pain as a possible complication of implant placement, particularly in patients with a significant medical history. Consideration should be given as to whether these patients are suitable for implant rehabilitation. Patients reporting very severe and prolonged postoperative pain following implant surgery should be considered at risk of CPSP and referred to a specialist in orofacial pain. PMID: 27314126 [PubMed - in pr...
Source: European Journal of Oral Implantology - June 19, 2016 Category: Dentistry Authors: Devine M, Taylor S, Renton T Tags: Eur J Oral Implantol Source Type: research

Patient Perceived Benefit in Facial Aesthetic Procedures: FACE-Q as a Tool to Study Botulinum Toxin Injection Outcomes
Conclusions The FACE-Q demonstrates that patients are more satisfied by their overall facial appearance and age appearance following neuromodulation of their glabellar rhytids. Patients are equally satisfied with the improvement of their facial appearance regardless of which neurotoxin they received. Level of Evidence: 2 Therapeutic (Source: Aesthetic Surgery Journal)
Source: Aesthetic Surgery Journal - June 17, 2016 Category: Cosmetic Surgery Authors: Chang, B. L., Wilson, A. J., Taglienti, A. J., Chang, C. S., Folsom, N., Percec, I. Tags: Original Article Source Type: research

[Botulinum toxin type A in headache treatment : Established and experimental indications].
This article summarizes the most important studies as well as experiences of treatment with botulinum toxin type A regarding different headache entities. PMID: 27300190 [PubMed - as supplied by publisher] (Source: Der Nervenarzt)
Source: Der Nervenarzt - June 14, 2016 Category: Neurology Authors: Gaul C, Holle-Lee D, Straube A Tags: Nervenarzt Source Type: research

Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: a single tertiary institution experience
To determine the effectiveness of submandibular salivary gland Botulinum Toxin Type-A (BTX-A) injection in the treatment of drooling in children with varying degrees of neurological dysfunction. (Source: International Journal of Pediatric Otorhinolaryngology)
Source: International Journal of Pediatric Otorhinolaryngology - June 11, 2016 Category: ENT & OMF Authors: Murali Mahadevan, Maayan Gruber, Darin Bilish, Kathryn Edwards, David Davies Payne, Graeme van der Meer Source Type: research

Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: A single tertiary institution experience
To determine the effectiveness of submandibular salivary gland Botulinum Toxin Type-A (BTX-A) injection in the treatment of drooling in children with varying degrees of neurological dysfunction. (Source: International Journal of Pediatric Otorhinolaryngology)
Source: International Journal of Pediatric Otorhinolaryngology - June 11, 2016 Category: ENT & OMF Authors: Murali Mahadevan, Maayan Gruber, Darin Bilish, Kathryn Edwards, David Davies-Payne, Graeme van der Meer Source Type: research

Patient satisfaction as an excellent track record in nonsurgical rejuvenation procedures.
CONCLUSIONS: The study findings support evidence of a more recently described increase in popularity in minimally invasive aesthetic procedures, of which combination therapy has the best performances with a good degree of satisfaction. PMID: 27249586 [PubMed - in process] (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - June 3, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses
Conclusions Although the studies had unclear or high risk of bias, moderate evidence regarding the efficacy of BoTN-A in treating TN and PHN was found. BoTN-A might be an alternative treatment to those patients who are either unable to manage their pain medically or would like adjunct therapy. (Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology)
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - June 1, 2016 Category: ENT & OMF Source Type: research

Botulinum toxin: A lift for chronic migraines
This article briefly reviews treatments for migraine and introduces the role of onabotulinumtoxin A (Botox A) in improving the management of chronic migraines. (Source: Journal of the American Academy of Physician Assistants)
Source: Journal of the American Academy of Physician Assistants - May 27, 2016 Category: Primary Care Tags: Review Article Source Type: research

RE: Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder
ABSTRACT Recurring priapism is rare in pre-pubertal children and may be attributed to multiple causes. We propose that voiding dysfunction (VD) may also justify this symptom and detail a clinical case of recurring stuttering priapism associated to overactive bladder that completely resolved after usage of anticholinergics and urotherapy. Sacral parasympathetic activity is responsible for detrusor contraction and for spontaneous erections and a relationship between erections and bladder status has been proved in healthy subjects (morning erections) and models of medullar trauma. High bladder pressures and/or volumes, voidin...
Source: International Braz J Urol - May 25, 2016 Category: Urology & Nephrology Source Type: research

Overactive bladder – 18 years – Part II
ABSTRACT Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were rec...
Source: International Braz J Urol - May 25, 2016 Category: Urology & Nephrology Source Type: research